Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human LYPD3 Antibody (SAA0109)

Catalog #:   FHB60010 Specific References (16) DATASHEET
Host species: Human
Isotype: IgG1, lambda
Applications: FCM
Accession: O95274
Overview

Catalog No.

FHB60010

Species reactivity

Human

Host species

Human

Isotype

IgG1, lambda

Clonality

Monoclonal

Conjugation

Unconjugated

Target

C4.4A, Matrigel-induced gene C4 protein, GPI-anchored metastasis-associated protein C4.4A homolog, MIG-C4, LYPD3, Ly6/PLAUR domain-containing protein 3

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O95274

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0109

Data Image
References

A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17)., PMID:39727484

A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy., PMID:35658441

Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/α-neurotoxin Domain., PMID:32140067

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer., PMID:31644911

Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer., PMID:28292941

New Blocking Antibodies against Novel AGR2-C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice., PMID:25646014

The metastasis-associated molecule C4.4A promotes tissue invasion and anchorage independence by associating with the alpha6beta4 integrin., PMID:23727360

C4.4A expression is associated with a poor prognosis of esophageal squamous cell carcinoma., PMID:23435632

Distinct expression of C4.4A in colorectal cancer detected by different antibodies., PMID:23175173

Expression of C4.4A in precursor lesions of pulmonary adenocarcinoma and squamous cell carcinoma., PMID:21792890

Expression of C4.4A, a structural uPAR homolog, reflects squamous epithelial differentiation in the adult mouse and during embryogenesis., PMID:21339181

Expression of C4.4A at the invasive front is a novel prognostic marker for disease recurrence of colorectal cancer., PMID:20825414

C4.4A as a candidate marker in the diagnosis of colorectal cancer., PMID:17912244

Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer., PMID:17706320

Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor., PMID:15012588

Cloning and functional characterization of a new phosphatidyl-inositol anchored molecule of a metastasizing rat pancreatic tumor., PMID:9788443

Datasheet
$ 225
Product specifications
50 μg 225 100 μg 372

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human LYPD3 Antibody (SAA0109) [FHB60010]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only